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Available online 24 October 2016Gaucher disease (GD), the most common lysosomal storage disease, is caused bymutations in GBA1 encoding of
β-glucocerebrosidase (GCase). Recently it was reported that progranulin (PGRN) insufﬁciency and deﬁciency as-
sociatedwith GD in human andmice, respectively. However the underlyingmechanisms remain unknown. Here
we report that PGRN binds directly to GCase and its deﬁciency results in aggregation of GCase and its receptor
LIMP2. Mass spectrometry approaches identiﬁed HSP70 as a GCase/LIMP2 complex-associated protein upon
stress, with PGRN as an indispensable adaptor. Additionally, 98 amino acids of C-terminal PGRN, referred to as
Pcgin, are required and sufﬁcient for the binding to GCase and HSP70. Pcgin effectively ameliorates the disease
phenotype in GD patient ﬁbroblasts and animal models. These ﬁndings not only demonstrate that PGRN is a
co-chaperone of HSP70 and plays an important role in GCase lysosomal localization, but may also provide new
therapeutic interventions for lysosomal storage diseases, in particular GD.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Pcgin1. Introduction
Gaucher disease (GD), a common lysosomal storage disease (LSD), is
caused by mutations in GBA1 with resultant defective
glucocerebrosidase (GCase) function and the consequent accumulation
of β-glucosylceramide (β-GlcCer) in macrophages and other cell types
(Brady et al., 1965; Platt, 2014). β-GlcCer storage transforms lysosomes
into tubular-like structures as viewed by electronic microscopy, with
the lipid-engorged macrophage (Gaucher cell) showing a characteristic
“wrinkled tissue paper” appearance under light microscopy. There are
three types of GD based on its neurological complications (Beutler,
1991). Type 1 GD, the most common, is a non-neuropathic form occur-
ring predominantly in patients of Ashkenazi Jewish descent; character-
istics include hepatosplenomegaly, thrombocytopenia, anemia,
osteonecrosis and sclerosis, diffuse osteopenia, and multiple osteologiciversity School of Medicine, 301
. This is an open access article undercomplications (Beutler, 1991). Type 2 (or acute infantile neuropathic
Gaucher's disease) begins within 6 months of birth and presents with
serious convulsions, hypertonia,mental retardation and apnea. Children
with Type 2 usually die before two years of age. Type 3 GD, a chronic
neuropathic form, can begin at any time in childhood or even in adult-
hood. It is characterized by slowly progressive, milder neurologic symp-
toms as compared to acute type 2 GD.
Progranulin (PGRN), also known as granulin, epithelin precursor
(GEP), PC-cell-derived growth factor (PCDGF), proepithelin, and
acrogranin, contains seven-and-a-half repeats of a cysteine-rich motif
(CX5–6CX5CCX8CCX6CCXDX2HCCPX4CX5–6C) and forms a unique
“beads-on-a-string” structure (Hrabal et al., 1996). PGRN is abundantly
expressed in epithelial cells, in chondrocytes, in cells of the immune sys-
tem, and in neurons (Bateman and Bennett, 2009). PGRN is known to
play a critical role in a variety of physiologic and disease processes, in-
cluding early embryogenesis, wound healing (He et al., 2003), and
host defense (Jian et al., 2013a). PGRN also functions as a neurotrophic
factor and mutations in the PGRN gene (GRN) resulting in partial or
complete loss of the PGRN protein were reported to associate withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and neuronal ceroid lipofuscinosis (NCL) (Ahmed et al., 2010; Gotzl et
al., 2014), respectively.
PGRN associateswith particularmembers in the TNF receptor super-
family, including TNFR1, TNFR2 and DR3 (Tang et al., 2011; Jian et al.,
2013b; Liu et al., 2014; Li et al., 2014), and possesses the ability to sup-
press inﬂammation in various conditions (Zhu et al., 2002; Tang et al.,
2011). Auto-antibodies against PGRN have been found in several auto-
immune diseases, including rheumatoid arthritis, psoriatic arthritis,
and inﬂammatory bowel disease, and such antibodies were shown to
promote a proinﬂammatory environment in a subgroup of patients
(Thurner et al., 2013; Thurner et al., 2014).
We recently reported that the four single nucleotide polymorphism
(SNP) sites in GRN, the gene encoding PGRN, lead to PGRN insufﬁciency
and have signiﬁcantly higher frequency in GD patients; revealing an as-
sociation between PGRN insufﬁciency andGD (Jian et al., 2016). In addi-
tion, “aged” and challenged adult PGRN null mice develop GD-like
phenotypes (Jian et al., 2016). However, the mechanisms underlying
the association between PGRN and GD remain unclear. In this study,
we report that PGRN is a co-chaperone for the lysosomal localization
of GCase under pathological conditions through linking GCase to heat
shockprotein 70 (HSP70), an evolutionarily highly conservedmolecular
chaperone that mediates folding and unlocks disaggregation of numer-
ous proteins (Rothman and Schekman, 2011; Nillegoda et al., 2015;
Nillegoda and Bukau, 2015; Matsuda et al., 2003; Parenti et al., 2015).
More importantly, a 15-kDa PGRN-derived protein, referred to as
Pcgin, effectively ameliorates the cellular phenotypes of GD.
2. Methods
2.1. Materials
Fibroblasts from Types 1 and 2 GD patients were purchased from
Coriell Cell Repositories (Camden, NJ). Airway epithelial cells from WT
and HSP70 KO mice were kindly provided by Dr. Lee (Zhang et al.,
2016). Antibodies against GCase (sc-100544, sc-30844, and sc-32883),
PGRN (SC-28928), Sortilin (sc-376576), α-GLA (sc-25823), HSP70 (sc-
373867), Calregulin (sc-373863), TGN38 (sc-271624), EEA1 (sc-
365652) LIMP2 (sc-55571), LAMP2 (sc-18822), His-tag (sc-803), GFP
(sc-8334), and DsRed (sc-33353) were purchased from Santa Cruz Bio-
technology (Dallas, Texas). Fluorescence labeled secondary antibodies
were purchased from Jackson ImmunoResearch Laboratories, Inc.
(West Grove, PA). Recombinant His-tag PGRN protein was puriﬁed
from 293T stable cell lines as described previously (Feng et al., 2010;
Tang et al., 2011). Recombinant GCase (Cat. No. 7410-GH-010), sortilin
(Cat. No. 3154-ST-050), and LIMP2 (Cat. No. 1966-LM-050) proteins
and sheep anti-mouse PGRN antibody (AF2557) were purchased from
R&D Systems (Minneapolis, MN). ELISA kits to detect murine TNF-α,
IL-1β, and IL-6 were purchased from eBioscience, Inc. (San Diego, CA).
2.2. Construction of Expression Plasmids
cDNAs encoding either full-length human PGRN or its serial N-ter-
minal or C-terminal deletion mutants were cloned into pEGFP-N1 vec-
tors by using EcoRI and BamHI sites. The amino acid number encoded
by C-terminal Deletions (CD) constructs: full-length PGRN (aa 1-593),
CD1 (aa 1-521), CD2 (aa 1-444), CD3 (aa 1-376), CD4 (aa 1-284), CD5
(aa 1-209), CD6 (aa 1-127), and CD7 (aa 1-61). The amino acid number
encoded by N-terminal Deletions (ND) constructs: ND1 (aa 45-593),
ND2 (aa 113-593), ND3 (aa 179-593), ND4 (aa 261-593), ND5 (aa
336-593), ND6 (aa 416-593), and ND7 (aa 496-593). All constructs
were conﬁrmed by DNA sequence. Full-length human GCase was pur-
chased from Addgene (Cambridge, MA) and subcloned to pDsRed-
monomer N1 vector (Clontech Mountain View, CA). All constructs
were conﬁrmed by DNA sequencing.2.3. Preparation of Lipid Extraction
Mouse brain tissue was used as a source of lipidmixture. Brieﬂy, one
mouse brain was dissected under sterile conditions. The brain tissues
were homogenized in 50 ml DMEM medium containing 10% FBS.
Bicinchoninic acid assay was used to determine the protein level in
the brain lysate.2.4. Expression and Puriﬁcation of Pcgin
The sequence for Pcgin was inserted into pD444 expression vector
with a His-tag (from DNA2.0, Menlo Park, CA). Pcgin was expressed in
theBL21(DE3) E. coli strain after induction by 1mMIPTG. After a 3 h cul-
ture, cells were pelleted and sonicated to release the fusion protein. His-
tagged Pcgin was puriﬁed by using ProBond™ Puriﬁcation System (Life
Technology, Carlsbad, CA) as we have previously described (Tang et al.,
2011). Brieﬂy, supernatant of cell lysiswas incubatedwith afﬁnity beads
overnight, andwashedwithwashing buffer (50mMNaH2PO4, 200mM
NaCl, 50 mM Imidazole, pH 8.0) six times. Pcgin was eluted from beads
with elution buffer (50 mM NaH2PO4, 200 mM NaCl, 250 mM Imidaz-
ole, pH8.0). After dialysis with PBS, endotoxin removal, and 0.2 μmﬁlter
sterilization, recombinant Pcgin protein was used in our cell-based
model and in vivo animal model.2.5. Site-directed Mutagenesis
pEGFP vector containing the Pcgin sequence was used as a template
to create serial deletion mutants using a site-directed mutagenesis kit
(Stratagene Ipswich, MA). Five deletion mutants were made to cover
the full-length Pcgin:Δ1 delete aa496-522,Δ2 delete aa523-534,Δ3 de-
lete aa535-539, Δ4 delete aa540-573 and Δ5 delete aa574-593. All mu-
tant constructs were conﬁrmed by DNA sequencing and their
expressions were examined by western-blot.2.6. Chronic Lung Inﬂammation Model
C57B/L6WT and PGRNKOmicewere housed in the animal facility of
New York University as previously described (Tang et al., 2011). All an-
imal experiments have been approved by Institutional Animal Care and
use Committee (IACUC) of New York University School of Medicine. 8
week-old mice were induced with chronic lung inﬂammation by intra-
peritoneal (I·P.) injection of OVA-Alum at Day 1 and Day 15, followed
by intranasal challenge with 1% OVA, beginning at Day 29 and adminis-
tered at a frequency of every three days for the duration of four weeks
(Daley et al., 2008).
To evaluate Pcgin's therapeutic function in vivo, a GDphenotypewas
induced in 8-week-old PGRN KOmice (n= 10) by OVA as described by
above. One group of mice were injected with Pcgin (4 mg/kg/week)
starting from the ﬁrst week of intranasal challenge until to the end of
this experiment and another group of micewere treated with Imigluce-
rase (60 u/kg/week) as a positive control. After 5 weeks of treatment
with Pcgin or Imiglucerase, mice were sacriﬁced and lung tissues were
ﬁxed and processed by Mass Histology Service (Worcester, MA).2.7. Right Ventricular Systolic Pressure (RVSP)
The right jugular veins of anesthetizedWT and PGRN KOmice were
exposed under an anatomic microscope. The RVSPwasmeasured as re-
ported previously (Park et al., 2015). Brieﬂy, a catheterwas inserted into
right ventricular chamber via the jugular vein and RVSP was measured.
Mice were analyzed without prior knowledge of group identity. The
data from three independent experiments were pooled.
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After mice were sacriﬁced, lung tissues were embedded in parafﬁn,
cut into slides, and stainedwith H&E and PAS byMass Histology Service
(Worcester, MA). Quantiﬁcation of Gaucher cell count and measure-
ment of area occupied by Gaucher cells was analyzed by Image J
software.
2.9. Transmission Electron Microscope (TEM)
WT and PGRN KO mice after OVA treatment were anesthetized and
the lung was processed for TEM or immunogold EM staining at micro-
scope core facility at New York University School of Medicine (Jian et
al., 2016). Brieﬂy, mice were euthanized and the lung was perfused
with ﬁxative containing 2.5% Glutaraldehyde and 2% paraformaldehyde
in 0.1 M sodium cacodylate buffer (pH 7.2) for 2 h. The samples were
post ﬁxed in 1% OsO4 for 1 h, block stained with 1% uranyl acetate,
dehydrated and embedded in Embed 812 (Electron Microscopy Sci-
ences, Hatﬁeld, PA). 60 nm sections were cut, and stained with uranyl
acetate and lead citrate by standard methods. Stained grids were exam-
ined under Philips CM-12 electron microscope (FEI; Eindhoven, The
Netherlands) and photographed with a Gatan (4 k × 2.7 k) digital cam-
era (Gatan, Inc., Pleasanton, CA).
For immunoelectron microscopy, lungs were ﬁxed with 4% PFA in
0.1 M phosphate buffer (pH 7.4). The tissues were embedded in
Lowicryl K4M (Polysciences, Inc.,Warrington, PA) and LR White (Elec-
tron Microscopy Sciences, Hatﬁeld, PA). Polymerization was carried
out under UV light (360 nm) at −35 °C for LK4M and −10 °C for LR
White. After incubation with primary antibodies at 4 °C overnight,
gold conjugated secondary antibodies (15 nm Protein A Gold, Cell Mi-
croscopy Center, University Medical Center Utrecht, 35584 CX Utrecht,
The Netherlands; 18 nm Colloidal Gold-AfﬁniPure Goat Anti-Rabbit
IgG (H + L), Jackson ImmunoReasearch Laboratories, Inc., West Grove,
PA) were applied.
For double immunogold labeling, the tissue sections were incubated
with mouse antibodies against GBA, or HSP70, followed by incubation
with secondary antibody labeled with 5 nm gold particle. Then the sec-
tionswere incubatedwith rabbit anti-PGRN antibody, followed by incu-
bation with secondary antibody labeled with 18 nm gold particle. The
grids were stained and examined as described above.
2.10. Surface Plasmon Resonance (SPR)
Binding afﬁnity between GCase and PGRN were measured by SPR
experiments by SensiQ Technologies Inc. (Oklahoma City, OK) as previ-
ously described (Tang et al., 2011; Jian et al., 2013b).
2.11. Fluorescence Resonance Energy Transfer (FRET)
293 EBNA cells in 96-well plates were transfected with pDsRed-GBA
and pEGFP-PGRN·Cells transfected with pDsRed empty vector were
employed as baseline control. The ﬂuorescence intensity was read by
SpectraMax® i3x Platform from Molecular Devices (Sunnyvale, CA).
The cells were excited by GFP excitation wavelength (488 nm) and de-
tect the DsRed emission wavelength (588 nm).
2.12. Immunoﬂuorescence Staining and Confocal Microscope
Frozen lung sections, or cover-slip cultured cells, were ﬁxed with 4%
formaldehyde and permeabilized by 0.1% Triton-100 PBS. Primary anti-
bodies were probed at 4 °C degree overnight, followed by ﬂuorescence-
labeled secondary antibodies. The tissues or cultured cells were
mounted on anti-fade medium containing DAPI. The images were
taken by Leica TCS SP5 con-focal system.2.13. Immunoprecipitation
Lungs fromWT and PGRN KO mice with or without OVA challenge,
or in another experiment from control PGRN KO mice, or OVA-chal-
lenged PGRN KO mice with or without rPGRN treatment, were lysed
with RIPA lysis buffer containing protease inhibitors. The same amount
of proteins from each group of mice was mixed together to represent
the protein proﬁle of each group. 400 μg protein from mixed samples
were used for immunoprecipitation.
To determine the interaction between PGRN and GCase in cells, 293
EBNA cells were co-transfected with plasmids encoding Flag-tagged
PGRN and RFP-fused GCase. Cells were collected by RIPA buffer, lysates
were immunoprecipitated with anti-Flag antibody, and the protein
complexes were detected with anti-GCase antibody.
To dissect the domains of PGRN responsible for binding to GCase,
293 EBNA cells were transfected with the plasmids encoding GFP
fused full-length PGRN, or its serial deletion mutants, together with
an expression plasmid encoding RFP fused GCase. 48 h after transfec-
tion, the cells were lysed and samples were processed as described
above.
All the samples were incubated overnight with primary antibodies
and protein A/G agarose-beads, followed by thorough washing with
RIPA lysis buffer. The sampleswere run on SDS-PAGE. Targeted proteins
were probedwith antibody and visualized bywestern-blot. In some ex-
periments, the samples were sent to NYU Core Facility for Mass Spec-
trometry after immunoprecipitation.2.14. Mass Spectrum
1) Gel Separation and Digestion. Samples were reduced with
DTT at 57 °C for 1 h and were alkylated with Iodoacetamide for
45 min. Each sample was loaded onto a NuPAGE® 4–12% Bis-Tris
Gel 1.0 mm The gel was stained using GelCode Blue Stain Reagent
(Thermo Scientiﬁc) and Coomassie stained gel bands were excised
as indicated on the gel image. Excised gel pieces were destained
with a 50:50 v/v solution of methanol and 100 mM ammonium
bicarbonate. 300 ng of trypsin (Promega) were added to digest
the gel pieces. 2) Protein Extraction. A slurry of R2 20 μm Poros
beads (Life Technologies Corporation) in 5% formic acid and 0.2%
triﬂuoroacetic acid (TFA) was added to each sample. The samples
were shaken at 4 °C for 2 h. The beads were loaded onto equilibrat-
ed C18 ziptips (Millipore) using a microcentrifuge for 30 s at
6000 rpm. Gel pieces were rinsed three times with 0.1% TFA. The
extracted porors beads were further washed with 0.5% acetic acid.
Peptides were eluted by the addition of 40% acetonitrile in 0.5%
acetic acid followed by the addition of 80% acetonitrile in 0.5%
acetic acid. The organic solvent was removed using a SpeedVac con-
centrator and the sample reconstituted in 0.5% acetic acid. 3) MS
Analysis. 1/5th of each sample was analyzed individually with the
mIgG analyzed ﬁrst, then the KO GBA, and ﬁnally the WT GBA. Sam-
ples were injected for on-line LC-MS using the autosampler of a
EASY-nLC 1000 (Thermo Scientiﬁc). Peptides were gradient eluted
from the column directly to Q Exactive mass spectrometer (Thermo
Scientiﬁc) using a 1 h gradient Solvent A: 5% acetonitrile, 0.5%
acetic acid Solvent B: 95% acetonitrile, 0.5% acetic acid. 4) MSMeth-
od. High resolution full MS spectra were acquired with a resolution
of 70,000, an AGC target of 1e6, with a maximum ion time of
120 ms, and scan range of 300 to 1500 m/z. Following each full MS
twenty data-dependent high resolution HCD MS/MS spectra were
acquired. All MS/MS spectra were collected using the following
instrument parameters: resolution of 17,000, AGC target of 2e5,
maximum ion time of 250 ms, one microscan, 2 m/z isolation window,
ﬁxed ﬁrstmass of 150m/z, andNCE of 27.MS/MS spectrawere searched
against a UniProt mouse database using Sequest within Proteome
Discoverer.
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Parafﬁn-embedded lung slides fromWT and PGRNKOmicewere de-
parafﬁned in a xylene and ethanol gradient. After antigen retrieval by
0.1% trypsin and inactivation of endogenous hydrogen peroxidase, the
slideswere blockedwith 3% BSA and 20% goat serum for 30min. Primary
antibodies were diluted at 1:20–50 with 2% goat serum and primed on
the slides at 4 °C overnight. The next day, slides were washed with PBS
and secondary antibodies were added (1:200 biotin-labeled goat-anti
rabbit antibody or goat-anti mouse antibody) for 1 h. The staining was
visualized by Vector ABC peroxidase kit, followed by DAB substrates.
2.16. Fluorescence Labeling of Active Form of GCase
MDW933, a speciﬁc ultrasensitive ﬂuorescent dye for active lyso-
somal GCase (Witte et al., 2010; Gaspar et al., 2014), was a kindly pro-
vided by Dr. Hermen E. Overkleeft at University of Leiden. Cells were
cultured on cover glass, andMDW933 (50 nM)was added in cell culture
medium for 2 h to label lysosomal GCase. Next, cells were ﬁxed with 3%
(v/v) paraformaldehyde in PBS for 15 min, permeabilized by 0.1 mM
NH4Cl in PBS for 10 min, Cells were mounted with DAPI-medium, and
ﬂuorescence was visualized under a confocal microscope.
2.17. Knockdown of PGRN and HSP70 by siRNA
siRNA against mouse PGRN and HSP70 were purchased from Life
Technology. 20 pmol of each siRNA were transiently transfected into
RAW264.7 cells by Lipofectamine 2000. The cells were treated with
lipid mixture (50 μg/ml) for 24 h and the level of the active form of
GCase was measured by MDW933 dye. The knockdown of PGRN or
HSP70was conﬁrmed by immunoﬂuorescence staining using their spe-
ciﬁc antibodies.
2.18. Lysosome Staining in LSD Fibroblasts
Fibroblasts from GD patients were cultured on coverslips in 24-well
plates, and challengedwith lipid lysis (50 μg/ml),with PGRN(0.4 μg/ml)
or Pcgin (5 μg/ml) for 24 h. The next day, fresh medium containing
100 nM LysoTracker® Red was added for 1 h. The cells were washed
with PBS and ﬁxed in 2% PFA. The coverslips were mounted on slides
and the staining of lysosomes was imaged by confocal microscopy.
Ten images were randomly taken from each sample, and ﬂuorescence
intensities were measured by ImageJ software.
2.19. Lysosome Staining by Live Imaging System
Full-length PGRN, as well as its serial deletion mutants, was cloned
into pEGFP vector, and transiently transfected into GD ﬁbroblasts seed-
ed in Lab-Tek Chamber cover glass system. After 48 h in culture,
LysoTracker® Deep Red (50 nM) was added to the medium for 1 h.
The LysoTracker Deep Red signaling (excitation/emission of 647/
668 nm) was observed in live cells by Applied Precision Personal DV
live-cell imaging system at NYU core facility.
GFP+positive cells indicated the expression of PGRN or its mutants,
and GFP− negative cells were un-transfected control cells. The thera-
peutic effect of PGRN, as well as its mutants, was evaluated by compar-
ing the LysoTracker signal between GFP+ and GFP− cells. Ten images
were taken for each sample, and ﬂuorescence intensity of lysosome of
GFP+ and GFP− cells were selected and quantiﬁed by ImageJ.
2.20. GlcCer Quantitation
GlcCer contents in cell and spleen were quantitated by LC/MS fol-
lowing glycosphingolipids extraction as described (Sun et al., 2005). In-
ternal standard of D5-C18-GlcCer was added prior to extraction. LC/MS
was carried out on a Waters Quattro Premier XE triple quadruple massspectrometer interfacedwith Aquity UPLC system (Milford,MA). GlcCer
were quantiﬁed using 3GlcCer reference standards (C16, C18 and C24-1
GlcCer) based onmultiple reactionmonitoring (MRM) function onmass
spectrometer. Quantiﬁcation of GlcCer with various chain lengths was
accomplished using the curve for the GlcCer of closest chain length.
Total GlcCer was the sum of individual GlcCer species detected. The
GlcCer levels were normalized by protein amount in the cells and by tis-
sue weight in spleen.
2.21. Statistical Analysis
For comparison of treatment groups, we performed unpaired t-tests,
paired t-tests, and one-way or two-way ANOVA (where appropriate).
All statistical analysis was performed using SPSS Software. Statistical
signiﬁcance was two-sided and was achieved when at p b 0.05.
3. Results
3.1. PGRN is Required for GCase Lysosomal Appearance and Its Deﬁciency
Causes GCase/LIMP2 Aggregation
The ﬁndings that PGRN plays important anti-inﬂammatory and im-
munoregulatory roles in various conditions, including inﬂammatory ar-
thritis (Tang et al., 2011), prompted us to examine its involvement in
chronic lung inﬂammation. For this purpose, chronic lung inﬂammation
was induced in 8-week oldWT and PGRN knockout (KO)mice by intra-
peritoneal (IP) injection of ovalbumin (OVA) at Day 1 and 15, followed
by intranasal challenge of 1% OVA three times aweek for four weeks be-
ginning at Day 29. PGRN expression was induced inWTmice after OVA
challenge (Fig. S1a), and PGRN KOmice developedmore severe lung in-
ﬂammation, including increased levels of inﬂammatory cytokines, pul-
monary cell inﬁltration, and right ventricular systolic pressure (Fig.
S1b–f). Remarkably, large numbers of “giant cells” were found in the
lungs of PGRN KO mice, particularly after OVA treatment (Fig. 1a).
These cells were engorged with materials and had a “wrinkled tissue
paper” appearance, which is the typical morphology of Gaucher cells.
No such cells were found in WT mice, either with or without OVA chal-
lenge. The liver and spleen were larger in PGRN KO mice relative to
those in WT mice (Fig. 1b). In accordance with our previous report
that β-GlcCer is accumulated in the lung tissue of PGRN KO mice, lipid
composition analysis revealed that GlcCer (Jian et al., 2016), as well as
levels of GlcSph (glucosylsphingosine), were signiﬁcantly higher in
both lung and plasma of PGRN KO mice as compared to WT mice (Fig.
S2). These macrophages from PGRN KO mice were much larger than
those in WT mice, and the PGRN KO lysosome displayed the classic
Gaucher-like cell tubular shape, instead of a regular round shape, as
viewed under transmission electronic microscope (TEM) (Fig. 1c). The
transformation of lysosome from the normal round shape to a tubu-
lar-like structure was observed along with material accumulation (Fig.
S3). Other organelles, such asmitochondria and endoplasmic reticulum,
and other types of cells, such as type 1 and 2pneumocyte, appearednor-
mal (Figs. S4, S5), although defects inmitochondrial function have been
reported in GD (Gegg and Schapira, 2016; de la Mata et al., 2015). The
tubular-like structurewas conﬁrmed as lysosome through immunogold
EM staining with the lysosomal receptor Sortilin (Figs. S6).
Accumulation ofβ-GlcCer inGD is caused by reducedGCase enzymat-
ic activity or decreased GCase protein expression (Grabowski, 2012).
However the protein level and GCase enzymatic activity were not affect-
ed in PGRNKOmice (Jian et al., 2016). Immunohistochemistry staining of
GCase revealed that intracellular localization of GCase was dramatically
altered. Remarkably, GCase was aggregated in the cytoplasm in OVA-
challenged PGRN KO mice (Fig. 1d). Immunogold labeling TEM further
demonstrated that GCase was aggregated in PGRN null macrophages
(Fig. 1e). The speciﬁcity of GCase antibody was examined with
Gba1−/− tissues (Fig. S7). As a control for the immunogold labeling
TEM, Sortilin was found mainly to be clustered close to the cell plasma
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Fig. 1. PGRN is required for GCase lysosomal appearance and its deﬁciency causes GCase/LIMP2 aggregation.WT and PGRNKOmice received I.P. injection of OVA at Day 1 and 15, followed
by intranasal challenge of 1%OVA beginning at Day 29 and administered thereafter three times aweek for fourweeks. (a) H&E staining shows giant Gaucher-like cells in lung of bothmale
and female PGRNKOmice, especially after OVA treatment. (n=10, 5male and 5 female for each group). (b) Spleen and liver are larger in OVA-challenged PGRNKOmice than inWTmice
(n = 10, 5 male and 5 female for each group). (c) Macrophages from PGRN KOmice are much larger than those in WT mice, and lysosomes become a tubular-like shape instead of the
regular round shape, as assayed by transmission electronic microscope (TEM). (d) Distribution of GCase is altered in PGRN KOmacrophages. Parafﬁn-embedded lung slides from OVA-
challenged mice were stained with GCase antibody by immunohistochemistry. The aggregation of GCase in PGRN KO macrophages is indicated with arrows. (e) GCase is aggregated in
the cytoplasm in of PGRN null macrophage, assayed by immunogold labeling of lung tissue. (f) The membrane of the aggregation structure in PGRN KO mice under EM. Lung tissues
from PGRN KO mice after OVA challenge were processed for EM scanning. The membrane structure around aggregates is indicated by the red arrow. (g) Expression of LIMP2 and
LAMP2 in macrophages from OVA-challenged WT and PGRN KO mice. Parafﬁn-embedded lung slides from WT and PGRN KO mice were stained with LIMP2 and LAMP2 by
immunohistochemistry. Aggregation of LIMP2 in PGRN KO macrophages was indicated with an arrow. (h) LIMP2, but not LAMP2, is aggregated in the cytoplasm of PGRN null
macrophage, assayed by immunoﬂuorescence staining. Frozen sections of lung tissue from OVA-challenged PGRN KO mice were stained with LIMP2 or LAMP2 antibodies by
immunoﬂuorescence. The aggregation of LIMP2 is indicated with an arrow. The numbers of LIMP2 aggregates and Gaucher-like cells were counted and indicated as aggregates/100
Gaucher-like cells (right panel). (i) LIMP2 is not detectable in the lysosome and is aggregated in the cytoplasm in the PGRN null macrophage, assayed by immunogold labeling of lung
tissue. LIMP2 is detectable in the lysosome, indicated with an arrow, of WT macrophage (left panel, 53,000×), whereas it is aggregated in the cytoplasm of PGRN-null macrophage and
not observed in the tubular-like lysosome (middle panel 31,000×). An aggregation region of denser immunogold labeling is circled with a dashed line. The numbers of aggregates of
LIMP2 and Gaucher-like cells were counted and indicated as aggregates/50 Gaucher-like cells (right panel). (j) GCase binds to LIMP2 in the absence of PGRN in vivo, assayed by co-
immunoprecipitation (Co-IP). Lung tissue from both WT and PGRN KO mice were lysed and protein complexes were immunoprecipitated with anti-GCase antibody and detected with
anti-LIMP2 antibody.
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like lysosomes of Gaucher cells in PGRN KOmice (Fig. S6). TEM revealed
that the aggregation of GCase was environed, at least partially, in/on a
membrane structure (Fig. 1f). We also performed co-immunogold stain-
ing of GCase with various organelle markers, including ER, trans-Golgi
network, lysosome, and autophagy markers. Intriguingly, GCase was
found to be speciﬁcally co-localized with the autophagy marker LC3 in
aggregates (Fig. S8). Taken together, these results demonstrate that the
lysosomal localization of GCase depends on the presence of PGRN.
Lysosomal integral membrane protein 2 (LIMP2), known as a GCase-
binding receptor thatmediates delivery of GCase to lysosomes, is present
in several subcellular organelles in the secretory pathway, including the
lysosome (Reczek et al., 2007). Interestingly,we found that lysosomal lo-
calization of LIMP2was also defective inOVA-challenged PGRN-deﬁcient
macrophages (Fig. 1g, h). However, intracellular localization of lysosom-
al associated membrane protein-2 (LAMP-2), a lysosomal marker, was
not affected in OVA-challenged PGRN null macrophages. Speciﬁcally,
both LIMP2 and LAMP2 were detected in the lysosomes of WTmacrophages; however LIMP2 was aggregated, while LAMP2 was dis-
tributed normally, in PGRN nullmacrophages (Fig. 1g). Confocal staining
with frozen sections of lung tissues also demonstrated the aggregation of
LIMP2, but not LAMP2, in OVA-challenged (Fig. 1h) and aged (Fig. S9)
PGRN deﬁcient tissues. The cytoplasmic aggregation of LIMP2 was
further conﬁrmed with immunogold TEM staining (Fig. 1i). In addition,
GCase and LIMP2 still bind together in both WT and PGRN KO tissues
mice, as assayed by co-immunoprecipitation (Fig. 1j) and con-focal
staining (Fig. S10), which is in accordance with the previous reports
that indicating that sorting of GCase and LIMP2 are tightly linked
(Reczek et al., 2007). Collectively, both GCase and its receptor LIMP2
were aggregated and absent from lysosomes in stressed (OVA-
challenged or lipid-stimulated) PGRN deﬁcient macrophages and mice.
3.2. PGRN Directly Binds to GCase Through a Two-site Mechanism
The ﬁnding that PGRN was required for lysosomal localization of
GCase prompted us to determine whether PGRN directly associates
217J. Jian et al. / EBioMedicine 13 (2016) 212–224with GCase. In vivo interaction between PGRN and GCase was dem-
onstrated by co-immunoprecipitation with both transfected cells
(Fig. 2a) and native tissues from WT mice (Fig. 2b). TNFR2 was
employed as a positive control for binding to PGRN (Tang et al.,
2011; Jian et al., 2013b). We also determined whether PGRN directly
binds to GCase using a solid-phase binding assay with recombinant
PGRN and GCase. PGRN demonstrated dose-dependent binding and
saturation to liquid-phase GCase (Fig. 2c), whereas no direct interac-
tion between PGRN and LIMP2was detected (Fig. 2c). The binding af-
ﬁnity between PGRN and GCase was then measured using surface
plasmon resonance (SPR) with SensiQ Pioneer as described (Tang
et al., 2011; Jian et al., 2013b). The results demonstrated that PGRN
binds to GCase in a two-site model: The ﬁrst binding site exhibited
a very high binding afﬁnity (KD1 = 0.71 nM), whereas the second
one displayed a relatively weaker binding afﬁnity (KD2 = 360 nM),
at pH 7.4 (Fig. 2d). Intriguingly, these two binding sites responded
differently to pH changes: The afﬁnity for the high binding site
decreased, whereas afﬁnity for the weaker binding site increased,
during pH reduction in the trafﬁc process from endoplasmic reticu-
lum (ER), Golgi, and trans-Golgi network (TGN) of macrophages
(Fig. 2d, e), although GCase and PGRN co-localized in all of these in-
tracellular trafﬁc compartments, as revealed by immunoﬂuores-
cence staining (Fig. S11). Double labeling immunogold TEM also
showed that PGRN co-localized with GCase in the ER and lysosome
(Fig. 2f). Taken together, these results suggest that the probablea
b
e
d
c
Fig. 2. PGRN directly binds to GCase in a two-sites binding mechanism. (a) PGRN binds to GCas
GCase, assayed by co-immunoprecipitation (Co-IP). The cell lysates were immunoprecipitated
independent experiments. (b) PGRN binds to GCase assayed by Co-IP. Lung tissues from WT
TNFR2 (serving as a positive control) antibody, and probed with anti-PGRN antibody. (c) PGR
of PGRN were coated, and biotin-labeled BSA, LIMP2 and GCase were added, followed by
mechanism, and the binding afﬁnity responds differently to decreasing pH in trafﬁc, assayed
binding values of both high and low afﬁnity binding sites. (f) PGRN co-localizes with GCase i
tissue in WT mice. PGRN is labeled with 18 nm gold particle (large) and GCase is labeled withpoints of GCase and PGRN association are in the intracellular com-
partments, beginning in compartments as early as the ER.
To identify the domains of PGRN required for interactingwith GCase,
serial N-terminal deletions of PGRN were subcloned into pEGFP vector
and the expressions of these GFP fused deletion mutants of PGRN
were visualized with anti-GFP antibody (Fig. 3a, b). Co-IP was per-
formed to examine the binding activities of these mutants to RFP-
fused GCase encoded by the pDsRed-GCase plasmid (Fig. 3c). Deletion
of Grn P and Grn G did not affect, whereas deletion of Grn F abolished,
the interaction of PGRNwith GCase, indicating that Grn F of PGRN is in-
volved in the association between PGRN and GCase. Interestingly, fur-
ther removal of Grn B resulted in a weak recovery of interaction,
suggesting that Grn B might act as an inhibitory and regulatory domain
for binding to GCase. Further deletions demonstrated that Grn E
alone strongly bound to GCase (Fig. 3c). The binding pattern of these
N-terminal deletion mutants of PGRN with GCase was also conﬁrmed
by ﬂuorescence resonance energy transfer (FRET) assay (Fig. 3d).
Indeed, the importance of the major and strong binding site Grn E in
mediating the binding of PGRN to GCase was further demonstrated
with serial C-terminal deletions of PGRN, since deletion of Grn E from
C-terminus abolished the interaction in both Co-IP and FRET assays
(Fig. 3e–h). Collectively, these sets of assays indicate that Grn E and F
are the strong andweak binding sites, respectively, which also supports
the aforementioned two-site bindingmechanismof PGRN toGCase,ﬁrst
observed in our surface plasmon resonance (SPR) assay (Fig. 2d, e).f
ER
e in 293 EBNA cells transfected with plasmids encoding Flag-tagged PGRN and RFP-tagged
by anti-Flag antibody and probed with RFP antibody. The result is representative of three
mice were lysed and protein complexes were immunoprecipitated with anti-GCase or
N directly binds to GCase in vitro, assayed by solid phase binding assay. Various amounts
HRP-labeled Streptavidin and its substrates. (d) PGRN binds to GCase in a two-site
by surface plasmon resonance (SPR) with COOH1 chips. (e) Effect of assay pH on kinetic
n ER and lysosome in the macrophage, assayed by double immunogold labeling of lung
5 nm gold particle (small), co-localizations are indicated by arrows.
Fig. 3. PGRNbinds to GCase throughGrn E andGrn F. (a) Schemeof constructs encoding serial GFP-tagged N-terminal deletionmutants of PGRN. ND1 (aa 45-593), ND2 (aa 113-593), ND3
(aa 179-593), ND4 (aa 261-593), ND5 (aa 336-593), ND6 (aa 416-593), and ND7 (aa 496-593). (b) Expressions of GFP-tagged N-terminal deletion PGRN fragments, examined by
immunoblotting with anti-GFP antibody. (c) Co-IP assay. 293 EBNA cells were transfected with pDsRed-GCase encoding RFP-fused GCase and corresponding plasmids encoding
various GFP-fused N-terminal deletions of PGRN, as indicated, and the cell lysates were immunoprecipitated with GFP antibody. The complexes were probed with anti-RFP antibody.
Control IgG (Ctrl) used as a negative control. NS indicates nonspeciﬁc binding. (d) FRET assay. 293 EBNA cells were transfected as described in (c), and the culture plate was scanned
by SpectraMax® i3x Platform with GFP excitation wavelength (488 nm) and DsRed emission wavelength (588 nm). (e) Scheme of constructs encoding serial GFP-tagged C-terminal
deletion mutants of PGRN. PGRN full-length (aa 1-593), CD1 (aa 1-521), CD2 (aa 1-444), CD3 (aa 1-376), CD4 (aa 1-284), CD5 (aa 1-209), CD6 (aa 1-127), and CD7 (aa 1-61). (f)
Expressions of GFP-tagged C-terminal deletion PGRN fragments, examined by immunoblotting with anti-GFP antibody. (g) Co-IP assay. 293 EBNA cells were transfected with pDsRed-
GCase encoding RFP-fused GCase and corresponding plasmids encoding various GFP-fused C-terminal deletions of PGRN, as indicated, and the cell lysates were immunoprecipitated
with GCase BA antibody. The complexes were probed with anti-GFP antibody. The positive band is indicated with an arrow. HC indicates IgG heavy chain. (h) FRET assay. 293 EBNA
cells were transfected as described in (g), and the culture plate was scanned by SpectraMax® i3x Platform with GFP excitation wavelength (488 nm) and DsRed emission wavelength
(588 nm).
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We next sought to further determine the molecular mechanism by
which PGRN deﬁciency leads to the aggregation of GCase. To isolate
themolecules that are involved in PGRN's regulation of GCase, immuno-
precipitation was performed with anti-GCase antibody from OVA-chal-
lengedWT and PGRN KO tissues, followed by mass spectrometry (MS).
Immunoprecipitation with GCase antibody pulled-down both PGRN-
dependent and PGRN–independent GCase-associated proteins in WT
tissues. When the same immunoprecipitation experiment was per-
formed in PGRN KO tissues, only PGRN-independent GCase-associated
proteinswere immunoprecipitated. Hits fromWTmicewere subtracted
by hits from PGRN KO, to yield PGRN-dependent GCase associated pro-
teins, with the rationale that themolecules involved in PGRN-mediated
GCase localizationwould be among the hits only present inWTmice but
not PGRN KO mice (Fig. 4a). 134 hits in WT mice and 114 hits in PGRN
KO mice were identiﬁed. 95 of them were common in both groups,and 39 proteins were found to be speciﬁc for WT mice, suggesting
that these proteins would be PGRN-dependent GCase-associated
proteins (Fig. 4b). Perlecan and Leukocyte elastase inhibitor, two
known PGRN-binding proteins (Zhu et al., 2002; Gonzalez et al.,
2003), were identiﬁed among the 39 hits, validating the technique.
In addition, HSP70 and its co-chaperone protein T-complex protein
1 subunit alpha (TCP1), as well as cytoskeleton, vesicle-trafﬁc relat-
ed proteins, and an energy producing enzyme, were among the 39
hits (Table S1). These data were followed up with the studies in
HEK293EBNA cells stably transfected with an expression plasmid
encoding His-tagged PGRN (Tang et al., 2011). Two proteins were
co-puriﬁed with His-tagged PGRN, and MS analysis revealed that
these were HSP70 and TCP1 (data not shown). To conﬁrm the MS
data, we conducted immunoprecipitation using an anti-GCase anti-
body in WT and PGRN KO tissues, and probed with an antibody
against HSP70. HSP70 bound to GCase in WT mice after OVA
challenge, and this interaction was undetectable in PGRN KO mice
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Fig. 4. Stress-induced PGRN-dependent interaction between GCase and HSP70. (a) The scheme of themethod used to identify potential molecules involved in PGRN-mediated regulation
of GCase, i.e. PGRN-dependent GCase associated proteins. Immunoprecipitationwas performedwith GCase antibody from both OVA-challengedWT and PGRN KOmice, followed by high-
sensitivity mass spectrometry. (b) Summary of the hits isolated from both WT and PGRN KO mice and identiﬁcation of HSP70 as a PGRN-dependent GCase-associated chaperone. (c)
Binding of GCase to HSP70 is PGRN-dependent. Immunoprecipitation was conducted with anti-GCase antibody in WT and PGRN KO mice, and probed with HSP70 antibody. The result
is representative of three independent experiments. (d) rPGRN restores the interaction between GCase and HSP70 in PGRN deﬁcient mice in vivo. Lung tissue lysates prepared from
OVA-unchallenged (Ctrl) or OVA-challenged PGRN KO mice treated with or without rPGRN were immunoprecipitated with anti-GCase antibody, and the presence of HSP70 in the
immunoprecipitated complex was probed with HSP70 antibody. The result is representative of three independent experiments. (e) PGRN is co-localized with HSP70 in macrophages.
Distribution of PGRN and HSP70 in BMDM were stained by the speciﬁc antibodies followed by ﬂuorescence secondary antibodies, the co-localization is quantiﬁed as PDM Value
(Product of the Differences from the Mean) shown in the lower right panel. (f) PGRN is co-localized with HSP70 in cytosol of macrophage, assayed by double immunogold labeling
TEM of lung tissue in WT mice. PGRN is labeled with 18 nm gold particle (large) and HSP70 is labeled with 5 nm gold particle (small), and the co-localizations are indicated by arrow.
(g) GrnE of PGRN is required for its binding to HSP70. A plasmid encoding GFP alone, GFP fused PGRN (FL) or C-terminal deletion of GrnE (CD1) mutation, was transfected into 293T
cells. The interaction between PGRN and HSP70 were measured by immunoprecipitation with anti-GFP antibody and detected with HSP70 antibody. The result is representative of
three independent experiments. (h) Suppression of PGRN and HSP70 via a siRNA approach markedly reduces the lysosomal GCase in living macrophage, assayed by MDW933 labeling.
RAW264.7 macrophages were transfected with siRNA speciﬁcally against PGRN or HSP70. Cells pre-treated with lipid stimulation were labeled with MDW933 probe for 2 h, and the
expression levels of PGRN and HSP70 were measured by immunoﬂuorescence staining. The cell transfected with corresponding siRNA is indicated with an arrow. (i) GCase is
aggregated in HSP70 deﬁcient cells, assayed by immunoﬂuorescence staining. Murine lung endothelial cells from wild-type (WT) and HSP70 knockout (KO) mice were stimulated
with lipid for 24 h. The cells were immunoﬂuorescence stained with anti-GCase antibody, and imaged under confocal microscope. The aggregation of GCase is indicated with an arrow.
The numbers of aggregates of GCase were counted and indicated as aggregates/100 cells (bottom panel). (j) Binding of LIMP2 to HSP70 is also stress-induced and PGRN-dependent.
Immunoprecipitation was conducted with anti-HSP70 antibody in OVA-challenged WT and PGRN KO mice, and probed with LIMP2 antibody. The result is representative of three
independent experiments.
219J. Jian et al. / EBioMedicine 13 (2016) 212–224(Fig. 4c). In addition, administration of rPGRN rescued the binding of
GCase to HSP70 in PGRN KO mice (Fig. 4d). HSP70 co-localized with
PGRN in macrophages (Fig. 4e, f). PGRN bound to HSP70, and dele-
tion of GrnE (i.e. CD1), known to be important for binding to GCase
(Fig. 3c, g), also abolished the binding to HSP70 (Fig. 4g). We also
examined whether HSP70 is required for the lysosomal localization
of GCase via suppression of HSP70 using a siRNA approach. Similar
to knockdown of PGRN (serving as a control), suppression of
HSP70 led to a reduction of lysosomal GCase detection, assayedwith the activity-based probe (ABP) MDW933, which can spontane-
ously cross membranes and allow sensitive and speciﬁc labeling of
active lysosomal GCase in living cells (Witte et al., 2010; Gaspar et
al., 2014; Aerts et al., 2011) (Fig. 4h). Further, immunoﬂuorescence
staining with anti-GCase antibody demonstrated clear aggregation
of GCase in lipid-stimulated HSP70 knockout cells, but not in the
WT cells (Fig. 4i), and lysotracker and MDW933 co-staining revealed
elevated lysosomal storage and reduced active GCase in HSP70 KO
cells as compared to control cells (Fig. S12).
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et al., 2007), together with the ﬁnding that both GCase and LIMP2 were
aggregated in PGRN deﬁcient macrophages (Fig. 1), led us to determine
whetherHSP70 also interactedwith LIMP2. Similar to GCase, LIMP2 also
associatedwithHSP70 inWT, but not in PGRNKO tissues (Fig. 4j). In ad-
dition, the interaction between LIMP2 and HSP70 is highly dependent
on OVA challenge.
3.4. Development of Pcgin, a PGRN-derived Protein, Retains the Binding Ac-
tivity to GCase and HSP70
The ﬁnding that PGRN acts as a co-chaperone of HSP70 and is re-
quired for disaggregation of GCase, together with the facts that chaper-
one-based treatments aiming to enhance GCase lysosomal localization
have proven to be a promising alternative to enzyme replacement treat-
ment (ERT) and substrate reduction therapy (SRT) for GD (Zimran et al.,
2013; Sanchez-Fernandez et al., 2016; Jung et al., 2016; Mena-Barragan
et al., 2015), and recombinant HSP70 has been shown to effectively cor-
rect altered lysosomal stability seen in Niemann–Pick B disease (NPD)
(Kirkegaard et al., 2010), promoted us to examine whether PGRN
would have therapeutic effects in GD. Indeed, we have found that re-
combinant PGRN protein is therapeutic against Gaucher disease (Jian
et al., 2016). However, there is concern for the long-term usage of
PGRN as a drug due to potential oncogenic activity of this growth factor
and the established elevation of PGRN levels in various cancer tissues
relative to healthy counterparts (Bateman and Bennett, 2009; He and
Bateman, 1999; He et al., 2002; Zhou et al., 2015). To address this
issue, we devoted considerable effort toward developing a PGRN-de-
rived molecule that retains the GCase-binding and therapeutic activity
of PGRN but lacks its oncogenic action. For this purpose, numerous
PGRNmutants (i.e., C-terminal deletions, N-terminal deletions, internal
deletions, and various combinations)were generated, and their interac-
tions with GCase were tested. According to a series C-terminal and N-
terminal deletion mutants, a C-terminal 98 amino acid fragment (from
aa 496–593) of PGRN, containing Grn E domain, was found to be both
required and sufﬁcient for binding to GCase (Fig. 3). We next examined
whether Grn E also is the functional domain that mediates PGRN's ther-
apeutic effect against GD. Type 2 GD ﬁbroblasts (L444P) were
transfected with plasmids encoding GFP alone (negative control),
PGRN-GFP and CD1-GFP (deletion of Grn E domain, Fig. 3e), and the cor-
rection of lysosomal storage was analyzed with LysoTracker Deep Red.
By comparing the lysosomes in the transfected (GFP+) and non-
transfected (GFP−) cells, we found that lysosomal storage was signiﬁ-
cantly reduced in cells expressing PGRN-GFP, compared to non-
transfected cells. Interestingly, the Grn E domain is also required for
PGRN-mediated therapeutic function, as the transfection of CD1-GFP,
similar to the transfection with GFP empty vector, did not show any
therapeutic effect (Fig. 5a, b).
To identify the “minimal fragment” that retains GCase-binding and
therapeutic activity of PGRN, we dissected C-terminal 98-aa fragment
with ﬁve ﬁne-tune deletions (Fig. 5c, d). Deletion of the linker on the
left, i.e. Δ496–522, the region of aa540–573 and the linker on the right
of GrnE, i.e. Δ574–593, did not affect the binding to GCase and HSP70
(Fig. 5c, d), but abolished the molecule's therapeutic effects in type 2
GD ﬁbroblasts (L444P) (Fig. 5e, f), suggesting that these regions may
be needed for maintaining the proper functional conformation. Howev-
er, deletion of 12 (aa523–534) and of 5 (aa535–539, RDNRQ) amino
acid fragments completely abolished the binding activity to GCase and
HSP70, respectively, indicating these 12 amino acids and the RDNRQ
motif are responsible for binding to GCase and HSP70, respectively. In-
triguingly, deletion of these critical motifs/fragments led tomore severe
phenotypes as compared to controls (Fig. 5e, f), suggesting that these
mutants might act as the dominant negatives of endogenous PGRN.
Taken together, these results suggest that the C-terminal 98 amino
acid fragment appears to be the “minimal” molecule that retains
GCase-binding and functional activities. This molecule was referred toas Pcgin (PGRN C-terminus for GCase Interaction). The structure and
amino acid sequence of Pcgin are shown in Fig. 5g.
3.5. Pcgin Effectively Ameliorates the Phenotypes of GD
Pcginwas expressed in bacteria and puriﬁed as a His-tagged protein.
The purity was examined by Coomassie Blue staining of SDS-PAGE
electrophoresis gels and conﬁrmed by Western blotting with His
probe (Fig. 6a). Using a solid phase binding assay (Fig. 6b), we found
that recombinant Pcgin directly bound to GCase, HSP70 and sortilin
(known to bind to the last three amino acids QLL of PGRN and serving
as a positive control) (Zheng et al., 2011). Although Pcgin retained the
GCase and HSP70 binding activity of PGRN, it lacked PGRN's oncogenic
activity, including PGRN-activated oncogenic signaling and cell prolifer-
ation (data not shown).
Since overexpression of Pcgin signiﬁcantly reduced lysosomal stor-
age in type 2 GD ﬁbroblasts (L444P) (Fig. 5e, f), we next examined the
therapeutic effects of recombinant Pcgin in GD ﬁbroblasts. Similar to
PGRN, recombinant Pcgin signiﬁcantly reduced lysosomal storage con-
tent in the ﬁbroblasts from type 2 GD L444P ﬁbroblasts (measured by
LysoTracker intensity recorded via plate reader) (Fig. 6c) and D409H
ﬁbroblasts(measured by ﬂuorescencemicroscopy, followed by quantiﬁ-
cation) (Fig. 6d, e). In addition, Pcgin also effectively increased the lyso-
somal localization of mutant GCase (N370S) in type 1 GD ﬁbroblasts,
visualized byMDW933 labeling (Fig. 6f, g). Pcgin also reduced lysosome
storage and increased lysosomal localization of mutant GCase (L444P)
in type 2 GD ﬁbroblasts (Fig. 6h). In addition, Pcgin treatment led to sig-
niﬁcant reduction in β-GlcCer storage and increase of GCase activity in
type 2 GD ﬁbroblasts (L444P) (Fig. 6i, j).We also examined Pcgin's ther-
apeutic effect in the animal model. GD phenotype was induced by OVA
challenge in 8-week-old PGRN deﬁcientmice as described above (n=6
per group). Pcgin (4mg/kg/week)was I.P injected starting from the ﬁrst
week of intranasal challenge and continuing for 5weeks, atwhich point,
themice were sacriﬁced. Another groupwas injected with imiglucerase
as a positive control. In the untreated group,mice developed severeGD–
like phenotype and large Gaucher cells occupied lung tissues. However,
histology of lung tissue revealed dramatic improvement in the Pcgin
treated group (Fig. 6k). Quantiﬁed data reveals that Pcgin signiﬁcantly
reduced number and size of Gaucher cells (Fig. 6l, m). Lipid composition
analysis conﬁrmed that Pcgin signiﬁcantly reduced β-GlcCer storage as
well (Fig. 6n). These results suggest that Pcgin may be a promising drug
candidate in treating Gaucher disease.
4. Discussion
Recently we reported that PGRN is a previously unrecognized factor
that associates with GD (Jian et al., 2016). Serum level of PGRN is signif-
icantly lower in GD patients than in healthy controls, andwe have iden-
tiﬁed 4 SNP sites whichmay contribute to the low levels of PGRN in GD
patients (Jian et al., 2016). In addition, aged PGRN null mice spontane-
ously developGaucher-like phenotypes (Jian et al., 2016). In the present
study, we demonstrate that PGRN directly bound to GCase and was es-
sential for the lysosomal appearance of GCase. In addition, HSP70,
known to be crucial in unlocking protein disaggregation (Nillegoda et
al., 2015; Nillegoda and Bukau, 2015), was isolated as one of numerous
GCase-associated proteins dependent on the presence of PGRN in our
unbiased proteomic screen. Interestingly, the interaction between
GCase andHSP70, aswell as their involvement in GD, had been reported
previously (Lu et al., 2011; Yang et al., 2014; Ingemann and Kirkegaard,
2014), although the nature of this association was unclear. In addition,
the binding of PGRN to HSP70 was also independently reported
(Almeida et al., 2011). Our studies disclosed PGRN as an indispensable
co-chaperone that links GCase/LIMP2 complex to HSP70. Although
PGRN binds to and co-localizes with GCase in all trafﬁc compartments,
as early as the ER and Golgi apparatus, the interactions of GCase/
LIMP2 with HSP70 highly depend on OVA challenge (Figs. 2, 4, Fig.
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Fig. 5. Development of Pcgin. (a) Overexpression of PGRN, but not its mutant lacking Grn E, signiﬁcantly reduces lysosomal storage in type 2 GD ﬁbroblasts (L444P). GD ﬁbroblasts were
transiently transfectedwith plasmid encoding either GFP alone, GFP fused PGRN, or itsmutant lackingGrnE (CD1-GFP), and LysoTracker®DeepRedwere added after transfection, and live
images were taken. Red color represents level of lysosome signal, and the green color reﬂects cells expressing GFP (vector) or GFP-fused proteins. Lysosomal content was compared
between GFP+ and GFP− cells. (b) Quantiﬁcation analysis of the therapeutic effects of PGRN and its mutant. Ten images were taken for each sample, and ﬂuorescence (FL) intensity of
lysosomal signals from GFP+ and GFP− cells were selected and quantiﬁed by Image J. The therapeutic effects were determined by comparison of the red ﬂuorescence intensity
between GFP+ and GFP− cells. (c) Scheme of Pcgin and its deletion mutants. (d) Co-IP assays for examining the binding of Pcgin and its mutants to GCase and HSP70. 293T cells were
transfected with plasmids encoding either GFP fused Pcgin, or its mutants, together with plasmids encoding RFP fused GCase and HSP70, and the protein complexes were
immunoprecipitated with GFP antibody and probed with RFP or HSP70 antibodies respectively. The bottom panel shows expression of Pcgin and its mutants in the transfected cells.
The result is representative of three independent experiments. (e) Evaluation of the therapeutic effects of Pcgin and its mutations in type 2 GD ﬁbroblasts (L444P). Fibroblasts from
type 2 GD were transiently transfected with pEGFP control vector, or plasmid encoding Pcgin or its mutants. LysoTracker® Deep Red was added after transfection, and live images
were taken by DV live-cell imaging system. GFP+ cells with reduced lysosome staining exhibit a green color, while GFP+ cells with a high level of lysosome staining give rise to a
yellow color (GFP+ cells are indicated with white arrow). (f) Quantiﬁcation analysis of the therapeutic effects of Pcgin and its mutants. Ten images were taken for each sample, and
ﬂuorescence intensity of lysosomal staining from GFP+ and GFP− cells were quantiﬁed by Image J. The therapeutic effects were determined by comparison of the red ﬂuorescence
intensity between GFP+ and GFP− cells. (g) Structure and sequence of Pcgin. Pcgin is derived from C-terminal human PGRN from aa496-593, containing Grn E and linker regions on
both sides (top panel). Sequence of Pcgin is shown in bottom panel. Linker regions and Grn E are highlighted in green and red, respectively. Binding sites of GCase, HSP70, and Sortilin
are indicated. One-way ANOVA was used to compare means among multiple groups (Data are represented as mean ± SEM, * p b 0.05; ** p b 0.01; two sided).
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LIMP2 complex through PGRN may be stress- or disease-dependent.
Under physiological conditions, GCase/LIMP2 associates with PGRN in
trafﬁc compartments, including ER/Golgi apparatus, and basal level of
HSP70 may not interact or marginally interacts with this complex.
Whereas under stressed or pathological conditions, such as OVA chal-
lenge, lipid stimulation and/or GBA1mutations, GCase/LIMP2 complex
aggregates in the cytoplasm (Fig. 1f), the HSP70 disaggregation system
will be recruited to GCase/LIMP2 complex through PGRN as an indis-
pensable co-chaperone, to unlock the disaggregation of GCase/LIMP2
complex. Thus, PGRN-dependent association with HSP70 is speciﬁcally
crucial for preventing the aggregation of the GCase/LIMP2 complex
under pathological conditions. It is also noted that the level of HSP70
is much higher than that of PGRN (Fig. 4f), indicating that the level of
PGRNmay be the rate-limiting step for HSP70-mediated disaggregation
of GCase/LIMP2 aggregates. Thus, it is conceivable that supplementingPGRN (Jian et al., 2016) or its derivative Pcgin may enrich or enhance
the utility of HSP70, leading to the effective amelioration of GD pheno-
types in various models tested (Figs. 6).
Although failing to recruit HSP70 disaggregation system to GCase/
LIMP2 complex may largely account for the OVA-induced GD-like phe-
notype in PGRN KOmice, some known functions of PGRNmay also con-
tribute to understanding the unexpected observations in OVA-
challenged PGRN KO mice. For instance, PGRN associates with TNF re-
ceptors and possesses the ability to suppress inﬂammation in various
conditions (Zhu et al., 2002; Tang et al., 2011; Jian et al., 2013b; Liu et
al., 2014; Li et al., 2014), the lack of PGRN thus likely leads to an abnor-
mal macrophage response during OVA-induced inﬂammation (Fig. S1).
In addition, inﬂammation is known to be involved in multiple
sphingolipid LSDs and anti-inﬂammatory drugs have beneﬁts in
treating LSDs when used alone or combined with other treatments
(Platt, 2014). Furthermore, PGRN has been implicated in ER-stress
Fig. 6. Pcgin is therapeutic against GD in vitro and in vivo. (a) Expression and characterization of recombinant Pcgin. The puriﬁed Pcginwas analyzed by Coomassie blue staining (left) and
Western blottingwith anti-His antibody (right). (b) Recombinant Pcgin directly binds to GCase and HSP70 (Solid phase binding). Pcginwas coated on a 96-well plate and incubatedwith
biotin-labeled GCase, HSP70, and Sortilin (serving as a positive control) respectively. Direct binding was detected by an ELISA-based method. (c) Pcgin reduces lysosomal storage as
measured by lysotracker intensity. Type 2 GD ﬁbroblasts (L444P) cultured in 96-well plates were stimulated with lipid lysis, and treated with Pcgin (5 μg/ml) or PGRN (0.4 μg/ml) for
24 h. The cells were stained with LysoTracker Red and the ﬂuorescence intensity read using SpectraMax i3x plate reader. This data is representative of at least three independent
experiments. (d) Pcgin reduces lysosomal storage in type 2 GD ﬁbroblasts (D409H). Fibroblasts from GD patients were stimulated with lipid, or lipid plus Pcgin (5 μg/ml) and PGRN
(0.4 μg/ml). Lysosomal storage was measured by LysoTracker staining. (e) Quantiﬁcation of (d). Ten images per sample were taken by ﬂuorescence microscope, and ﬂuorescence (FL)
intensity was measured by Image J software, and therapeutic effects were determined by statistical analysis. (f) Pcgin enhances lysosomal localization of mutant GCase (N370S). Type
1 GD ﬁbroblasts were treated with Pcgin (5 μg/ml) for 24 h, and the lysosomal GCase was detected with its speciﬁc ﬂuorescence probe MDW933. (g) Quantiﬁcation of (f). Ten images
per sample were taken by ﬂuorescence microscope, and ﬂuorescence (FL) intensity was measured by Image J software, and therapeutic effects were determined by statistical analysis.
(h) Pcgin enhances lysosomal GCase and reduces lysosomal storage as measured by live imaging system. Type 2 GD ﬁbroblasts (L444P) were cultured in a live cell imaging chamber
and treated with Pcgin (5 μg/ml), or PGRN (0.4 μg/ml) for 24 h. MDW933 and LysoTracker were added and images were taken under live-cell imaging system. (i) Pcgin reduces β-
GlcCer storage in GD ﬁbroblasts. Type 2 GD ﬁbroblasts (L444P) were stimulated with lipid lysis, along with Pcgin (5 μg/ml), or PGRN (0.4 μg/ml) treatment for 24 h. The ﬁbroblasts
were collected for β-GlcCer analysis. (j) Pcgin increases GCase activity in GD ﬁbroblasts. Type 2 GD ﬁbroblasts (L444P) were treated as in (i), The GCase enzymatic activity was
measured. (k) Pcgin is therapeutic against GD-like phenotype in OVA-challenged PGRN KO mice. A GD-like phenotype was induced in PGRN KO mice, and mice were treated with
either Pcgin or Imiglucerase (serving as a positive control) (n = 6 per group). Lung tissues were examined by H&E staining. Gaucher cell number (l) and Gaucher cell sizes (m) were
signiﬁcantly reduced after Pcgin treatment. (n) Pcgin reduces β-GlcCer storage in OVA-challenged PGRN KO mice. Spleens of PGRN KO mice from (k) were used to measure the levels
of β-GlcCer. One-way ANOVA was used to compare means among multiple groups (Data are represented as mean ± SEM, * p b 0.05; ** p b 0.01; two sided).
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role in cell death in GD (Wei et al., 2008). The loss of PGRN leads to the
abnormal ER stress responses and the aggregation of various proteins in
the cytoplasm, such as TDP-43 (Baker et al., 2006; Tanaka et al., 2014)
and GCase/LIMP2 (this paper). Recently, it was reported that RIPK3, a
component of the TNFR1 signaling complex that mediates necroptosis,
was also involved in the pathology of GD and inhibiting RIPK3 might
be a novel therapeutic approach for GD (Vitner et al., 2014). Thus,
PGRN's anti-TNF and anti-cell death activities may also contribute to
its therapeutic effects in GD and other LSDs.
Many GRN gene mutations have been reported, and most of these
mutations lead to reduced levels of PGRN (Kleinberger et al., 2013). In-
sufﬁciency of PGRN has been associated with many types of neurode-
generative diseases including FTD, Parkinson's disease (PD),
Alzheimer's disease, Multiple Sclerosis, and Amyotrophic LateralSclerosis (Petkau and Leavitt, 2014). Our ﬁnding that PGRN is an indis-
pensable co-chaperone of HSP70 disaggregation system required for ly-
sosomal localization of GCase/LIMP2 may also have relevance to the
pathology of neurodegenerative diseases. Mutation of the GRN gene
may directly affect the HSP70-based disaggregases (Nillegoda and
Bukau, 2015) and in turn lead to defects in the clearance of proteins as-
sociated with neurodegenerative diseases, such as TDP-43 and α-synu-
clein, or indirectly affect the function of lysosomes resulting from the
impairment of GCase lysosomal localization and consequent accumula-
tion of glucosylceramide (Platt et al., 2012). Thus, the identiﬁcation of
PGRN as a co-chaperone of HSP70 for GCase lysosomal appearance
may also help us to better understand the putative molecular mecha-
nisms underlying GRNmutation-associated neurodegenerative disor-
ders. Further, heterozygosity for mutations in the GBA1 gene may be a
risk factor for PD (Eblan et al., 2005), this indicates that there may
223J. Jian et al. / EBioMedicine 13 (2016) 212–224exist a functional and a genetic linkage between GRN and GBA1 genes,
and that their homozygous or heterozygous mutations cause or render
some carriers vulnerable to rare (i.e. GD) and/or common (i.e. PD)
diseases.
Although Pcgin is a 98 amino acid c-terminal PGRN fragment, it
demonstrates comparable therapeutic effects with PGRN in several
types of GD patient ﬁbroblasts bearing common GBA1 mutations
and our GD mouse model. Future investigations with additional GD
models are warranted to further test the therapeutic effect and safe-
ty of Pcgin. Pcgin possesses features that suggest it may compare
favorably to currently marketed GD drugs. For example, currently
marketed drugs are enzyme replacement or substrate reduction
therapies. In contrast, Pcgin functions as a co-chaperone of HSP70
and enhances the disaggregation and lysosomal appearance of mu-
tant lysosomal enzymes. Due to this alternate mechanism of action,
Pcgin may be effective for other LSDs in addition to GD. Additionally,
Pcgin's safety (lacking PGRN's potential oncogenic activity) and ease
of production (as a small ~15 kD recombinant protein) suggest that
it may be a viable cost-effective agent for the clinical treatment of
LSDs, in particular GD.
In summary, this study identiﬁes PGRN as a previously-unrecog-
nized molecule associated with GCase, thus providing a foundation for
future discoveries relating to this critical factor in GD and other lyso-
somal storage diseases. In addition, it also isolates PGRN as a co-chaper-
one of HSP70 disaggregation system, thus uncovering a unique strategy
to target this cardinal pathway ofmetabolic diseases.More importantly,
we have developed a PGRN derivative, Pcgin, which effectively amelio-
rates the phenotypes of GD in several preclinical models. With the con-
sideration that HSP70 is involved in a plethora of disease processes, the
identiﬁcation andmanipulation of this new co-chaperoneofHSP70may
lead to innovative therapeutics for LSDs, in particular GD, and other
metabolic pathologies and conditions.Author Contributions
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